Most pharma investors focus on pipeline updates and trial results. The real alpha comes from tracking patent expiration calendars years in advance. Full analysis on Catalyst's diversification options: https://vianews.market/corporate-earnings-risk/firdapse-patent-expires-february-2035-threatens-70-80-revenue-decline-for